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ABSTRACT
OBJECTIVE: To evaluate the growth parameters in infants who were born to 
HIV-1-infected mothers.
METHODS: The study was a longitudinal evaluation of the z-scores for the 
weight-for-age (WAZ), weight-for-length (WLZ) and length-for-age (LAZ) 
data collected from a cohort. A total of 97 non-infected and 33 HIV-infected 
infants born to HIV-1-infected mothers in Belo Horizonte, Southeastern 
Brazil, between 1995 and 2003 was studied. The average follow-up period 
for the infected and non-infected children was 15.8 months (variation: 6.8 to 
18.0 months) and 14.3 months (variation: 6.3 to 18.6 months), respectively. A 
mixed-effects linear regression model was used and was fi tted using a restricted 
maximum likelihood.
RESULTS: There was an observed decrease over time in the WAZ, LAZ and 
WLZ among the infected infants. At six months of age, the mean differences 
in the WAZ, LAZ and WLZ between the HIV-infected and non-infected infants 
were 1.02, 0.59, and 0.63 standard deviations, respectively. At 12 months, the 
mean differences in the WAZ, LAZ and WLZ between the HIV-infected and 
non-infected infants were 1.15, 1.01, and 0.87 standard deviations, respectively.
CONCLUSIONS: The precocious and increasing deterioration of the HIV-
infected infants’ anthropometric indicators demonstrates the importance of 
the early identifi cation of HIV-infected infants who are at nutritional risk and 
the importance of the continuous assessment of nutritional interventions for 
these infants.
DESCRIPTORS: Infant. Body Weights and Measures. Growth and 
Development. HIV Infections. Infectious Disease Transmission, Vertical. 
Cohort Studies.
Artigos Originais
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The vertical (mother-to-child) transmission of HIV-1 is 
the major route for infection in children; 11,796 cases 
of pediatric acquired immunodefi ciency syndrome 
(AIDS) have been reported in Brazil.a Initial studies on 
the transmission rate of HIV in this country reported a 
rate of 16% (95%CI: 13; 20).19 After the introduction 
of antiretroviral therapy (ART) for the prevention of 
mother-to-child transmission of HIV-1 (PMTCT), 
a signifi cant reduction in the transmission rate was 
observed. A multicenter study reported a transmission 
rate of 7.1% in 2001,12 although lower rates have 
been reported in single-center studies conducted in 
Southeastern Brazil.13,14,18
The assessments of a child’s weight at birth and of 
his or her growth are indicators of the child’s nutri-
tional status. Vertically HIV-infected children exhibit 
a similar weight and length at birth as non-infected 
children in developed countries,17 but the differences 
between the infected and non-infected children begin 
RESUMO
OBJETIVO: Avaliar os parâmetros de crescimento em lactentes nascidos de 
mães infectadas com o HIV-1.
MÉTODOS: Avaliação longitudinal dos z-escores peso-idade (PI), estatura-
idade (EI), peso-estatura (PE) foi realizada em uma coorte. Foram estudados 
97 lactentes não-infectados e 33 lactentes infectados nascidos de mães 
infectadas com o HIV-1 em Belo Horizonte, MG, de 1995 a 2003. O tempo 
mediano de seguimento para os lactentes infectados e não-infectados foi de 
15,8 meses (variação: 6,8 a 18,0 meses) e 14,3 meses (variação: 6,3 a 18,6 
meses), respectivamente. Utilizou-se o modelo de regressão linear de efeitos 
mistos ajustado por máxima verossimilhança restrita para construir as curvas 
de crescimento.
RESULTADOS: Os z-escores PI, EI e PE dos lactentes infectados com o HIV-1 
apresentaram decréscimo. Aos seis meses, a diferença média nos z-escores 
PI, EI e PE entre lactentes infectados e não-infectados com o HIV era, 
respectivamente, 1,02, 0,59 e 0,63 desvios-padrão. Aos 12 meses, a diferença 
média nos z-escores PI, EI e PE entre lactentes infectados e não-infectados 
era, respectivamente, 1,15, 1,01 e 0,87 desvios-padrão.
CONCLUSÕES: O comprometimento precoce e crescente dos indicadores 
antropométricos de crianças infectadas com o HIV-1 mostra a importância de 
identifi car precocemente crianças infectadas com o HIV que estão em risco 
nutricional e a necessidade de se avaliarem continuamente as intervenções 
nutricionais adotadas.
DESCRITORES: Lactente. Pesos e Medidas Corporais. Crescimento e 
Desenvolvimento. Infecções por HIV. Transmissão Vertical de Doença 
Infecciosa. Estudos de Coortes.
INTRODUCTION
a Boletim Epidemiológico AIDST. Brasília: Ministério da Saúde. Programa Nacional de DST e AIDS; 2008[cited 2010 Feb 23];5(1). Available 
from: http://bvsms.saude.gov.br/bvs/periodicos/boletim_epidemiologico2008.pdf
to emerge during their fi rst few months of life.9,16,17 A 
cohort study that was conducted in Belo Horizonte, 
Southeastern Brazil, revealed that the decrease in 
growth in weight, but not in length, in HIV-infected 
children in Brazil was larger than that reported in a 
European cohort, which likely refl ects background 
nutritional defi ciencies and co-infections.9
The assessment of growth in HIV-infected children is 
important to determine the disease stage and prognosis, 
to assess the effectiveness and toxicity of antiretroviral 
therapies and to study the nutritional implications of the 
HIV infection.5 Growth may be one of the most sensitive 
indicators of disease progression in children who are 
living with HIV/AIDS.3 Even in children who are taking 
antiretroviral drugs, the absence of growth is a poor 
prognostic indicator. Weight gain is also an important 
indicator of the effectiveness of antiretroviral therapy.21 
Anthropometric methods are useful to monitor disease 
progression and to assess the response to treatment.
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b Ministério da Saúde. Guia de tratamento clínico da infecção pelo HIV em crianças. Brasília; 2004. (Série Manuais, 18).
c World Health Organization. Anthro for personal computers, version 2, 2007: Software for assessing the growth and development of the 
world’s children. Geneva; 2007.
Studies involving infants born to HIV-1-infected 
mothers may provide useful insights into the nutritional 
implications of the infection and may contribute to the 
development of intervention strategies for this segment 
of the population.
The objective of the present study was to evaluate the 
growth parameters of infants who were born to HIV-1-
infected mothers.
METHODS
The present study included a single-center open cohort 
of children and began in June 1994. The data concer-
ning the pregnancy, labor, and clinical and longitudinal 
laboratory evaluation of these infants were routinely 
collected. The Universidade Federal de Minas Gerais 
(UFMG) Maternal, Pediatric and Adolescent HIV 
Clinic is a referral center for the treatment and care 
of the HIV-infected population living in the Belo 
Horizonte metropolitan area and in other cities in the 
state of Minas Gerais (Southeastern Brazil). In the 
present study, the medical information was collected 
by pediatricians who specialized in immunology and 
infectious diseases using a standardized instrument. The 
time that elapsed between medical appointments varied 
according to each child’s clinical conditions.
From 1995 to 2003, 300 HIV-infected children aged 
zero to 16 years were observed at the clinic. A total of 
130 infants (33 infected and 97 uninfected) who were 
born to HIV-1-infected mothers and were admitted 
within the fi rst three months of life were included in 
the analysis.
The average follow-up period for the infected and 
non-infected children was 15.8 months (variation: 6.8 
to 18.0 months) and 14.3 months (variation: 6.3 to 18.6 
months), respectively.
The determination of an HIV infection was based on 
the Brazilian National AIDS Program algorithm,a which 
considers the following as positive indicators: (a) the 
existence of two samples positive for HIV at two weeks 
of life according to a DNA–PCR (Amplicor®; Roche, 
Basel, Switzerland) or an RNA-PCR (NASBA®; 
Organon-Teknica, Boxtel, The Netherlands) method; 
(b) the persistence of HIV antibodies detected by an 
ELISA screening and a western blot at 18 months of 
age; or (c) the development, at any age, of a clinical 
condition compatible with AIDS according to the 
the 1994 Revised Classifi cation System for Human 
Immunodefi ciency Virus Infection in Children Less 
Than 13 Years of Age.6 The following criteria were 
used to establish the absence of an HIV infection: (a) 
two negative HIV DNA–PCR or RNA-PCR samples 
taken at ages two weeks to four months and four to six 
months; (b) two negative anti-HIV ELISA serum tests 
performed after six months of age, with a minimum 
interval of two months between the tests and (c) the 
absence of clinical conditions compatible with AIDS. 
All of the infants that were included in the present study 
were diagnosed with the infection or were confi rmed 
to have an absence of HIV infection.
The protocol that was adopted by the UFMG Pediatric 
HIV Clinic to prevent the vertical transmission of HIV 
consists of antiretroviral use from the 14th week of 
pregnancy, intrapartum AZT, and postpartum oral AZT 
to the infant for the fi rst six weeks of life.
The clinical and laboratory data (using standardized 
data forms) were coded and entered into a database.
The weight (in kilograms) and the length (in centi-
meters) of the non-infected infants and HIV-infected 
infants were measured by trained pediatricians during 
regular visits. The measurements were conducted 
according to standard procedures.22 An electronic 
pediatric scale (Indústria Filizola S/A, São Paulo, 
Brasil) with a 125 g to 15 kg weighing capacity and 
a 5 g accuracy was used to weigh the children. Each 
child’s body length was measured using a horizontal 
wooden stadiometer with the infant in the recumbent 
position. WHO Anthro softwarec (Version 2.02) was 
used to calculate the z-scores.
The non-infected children contributed 924 measure-
ments to the weight-for-age z-scores, 906 measure-
ments to the length-for-age z-scores and 906 measu-
rements to the weight-for-length z-scores. Children 
living with HIV/AIDS contributed 372 measurements 
to the weight-for-age z-scores, 326 measurements to 
the length-for-age z-scores and 321 measurements to 
the weight-for-length z-scores.
The mean values of the weights and lengths of the 
infected and non-infected children, which were 
measured at the time of birth, were compared using 
a Student’s t-test.1 The distribution of the categorical 
variables, according to the two clinical groups, was 
evaluated using chi-squared and Fisher exact tests.1 
The level of signifi cance was established at 5%. The 
HIV-infected children were classifi ed according to 
the 1994 Centers for Disease Control and Prevention 
Classifi cation for children under the age of 13.6 Due 
to the unbalanced data set, the analysis was conducted 
using a mixed-effects linear model for z-scores. A 
restricted maximum likelihood was used to fi t the 
models. The xtmixed function was used to determine 
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the estimates. The comparison of the models was based 
on the maximum likelihood ratio test. The effect of 
extra random terms was evaluated using the restricted 
maximum likelihood ratio test.20
The following covariates were included in the statis-
tical analyses: exposure to prophylactic antiretroviral 
therapy regimens (1 = yes, 0 = no), gender (1 = male, 
0 = female), clinical group (1 = HIV-infected, 0 = non-
infected), and age (in months).
The statistical analyses were performed using Stata 
9.0 software.
The  present study was approved by the Ethical Review 
Board of UFMG (Process 075/2002).
RESULTS
The distribution by sex of the infected and non-infected 
infants was similar across the groups (p = 0.77). Males 
accounted for 45.4% and 54.6% of the infected and 
non-infected infants, respectively. All of the infants 
were born at full-term (gestational age ≥ 36 weeks).
The average age of the infants at the fi rst medical 
appointment after birth differed between the infected 
and non-infected infants; the fi rst medical appoint-
ment for the infected infants occurred at 1.6 months 
(variation: 0.06 to 3.5 months), and the fi rst medical 
appointment for the non-infected infants occurred at 
0.9 months (variation: 0.2 to 3.5 months) (p = 0.008).
Figure 1. Observed weight and height by infection status. Belo Horizonte, Southeastern Brazil, 1995-2003.
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Figure 2. Observed weight-for-age, height-for-age and weight-for-length z-scores by infection status. Belo Horizonte, Southe-
astern Brazil, 1995-2003.
−
5
0
5
0 5 10 15 20 0 5 10 15 20
Uninfected children Infected children
W
ei
gh
t−
fo
r−
le
ng
th
 z
−
sc
or
e
Age (months)
bandwidth = . 8
−
5
0
5
0 5 10 15 20 0 5 10 15 20
Uninfected children Infected children
Le
ng
th
−
fo
r−
ag
e 
z−
sc
or
e
Age (months)
−
5
0
5
0 5 10 15 20 0 5 10 15 20
Uninfected children Infected children
W
ei
gh
t−
fo
r−
ag
e 
z−
sc
or
e
Age (months)
657Rev Saúde Pública 2011;45(4):652-60
Among the infected infants, 77.4% (24/31) were asymp-
tomatic, 16.1% (5/31) presented mild or moderate signs 
and symptoms of infection progression and 6.5% (2/31) 
presented an advanced infection progression at the fi rst 
medical appointment. The clinical evaluation that was 
conducted at 12 months of age for 26 of the infected 
infants indicated that 26.9% of the children presented 
signs and symptoms of an advanced infection. Among 
the 30 infected infants for whom clinical information 
was available, three died, and six developed AIDS. No 
deaths occurred among the non-infected participants. 
The children’s ages at the last medical appointment 
for the cases that ended in death were 6.8, 9.9 and 
17.8 months all of these children presented signs and 
symptoms of advanced disease.
Exposure to antiretroviral therapy for PMTCT was 
reported by 95.8% of the non-transmitting mothers 
and by 66.7% of the transmitting mothers (p < 0.0005). 
Twenty-three of the 33 infected infants were exposed 
to antiretroviral therapy during the follow-up period; 
seven of the infants were not exposed to this therapy. In 
addition, no information about the presence of antiretro-
viral therapy was available for three of the participants.
Dual nucleoside analogue reverse transcriptase inhi-
bitors (NRTI) were the initial regimen for eight of the 
subjects. The remaining 15 subjects were administered 
highly active antiretroviral therapy (HAART) as the 
initial therapy regimen. Twelve subjects were on a 
protease inhibitor (PI)-with the HAART regimen, and 
two were on a non-PI HAART regimen (two NRTI 
and one non-nucleoside analogue reverse transcriptase 
inhibitor). There were no changes in the initial antire-
troviral therapy regimen over the course of the study.
No statistically signifi cant differences in the weight (p 
= 0.15), length (p = 0.62), weight-for-age (p = 0.11), 
length-for-age (p = 0.68) and weight-for-length (p = 
0.13) z-scores at birth were observed between the full-
term infected and non-infected infants. The mean weight 
and length at birth were 3.1 (standard deviation – SD: 
0.4 kg) and 48.7 (SD: 1.4 cm), respectively, for the non-
infected infants and 3.0 (SD: 0.5 kg) and 48.6 (SD: 3.1 
cm), respectively, for the infected infants. The weight-
for-age, length-for-age and weight-for-length z-scores of 
the non-infected infants at birth were -0.52 (SD: 0.88), 
-0.44 (SD: 0.73), and -0.21 (SD: 1.21), respectively. The 
weight-for-age, length-for-age and weight-for-length 
z-scores of the infected infants were -0.83 (SD: 1.11), 
-0.56 (SD: 1.66) and -0.65 (SD: 1.55), respectively.
Figure 1 shows the height and weight measurements 
according to the HIV infection status, with the infected 
children growing more slowly than the uninfected 
children.
Figure 2 shows the weight-for-age, height-for-age and 
weight-for-length z-score measurements according to 
the HIV infection status, with the infected children 
growing more slowly than the uninfected children.
The variables clinical group (p < 0.0005), age (p < 
0.0005) and exposure to antiretroviral therapy for 
PMTCT (p = 0.003) were signifi cantly associated with 
the weight-for-age z-score in the univariate mixed-
effects linear regression analysis. The fi nal model 
(Table) shows a decrease in the weight-for-age z-score 
among the infected infants over time. The non-infected 
infants presented monthly average increases of 0.08 
SD in their weight-for-age z-score. At six months, the 
Figure 3. Observed weight-for-length z-scores by exposure to prophylactic treatment to prevent the vertical transmission of 
HIV. Belo Horizonte, Southeastern Brazil, 1995-2003.
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average difference in the weight-for-age z-score was 
1.02 SD between the infected and non-infected infants. 
At 12 months, the average difference in the weight-
for-age z-score between the infected and non-infected 
infants was 1.5 SD.
In the univariate mixed-effects linear regression 
analysis, only the clinical group (p = 0.0004) was 
signifi cantly associated with the length-for-age z-score. 
The age variable was included in the model to evaluate 
whether there was a longitudinal difference between 
the length-for-age z-scores of the infected and non-
infected infants. The fi nal model (Table) shows that the 
differences between the groups increased with age (p 
= 0.001). At six months, the average difference in the 
length-for-age z-score of the infected infants was 0.59 
SD when compared to that of the non-infected infants. 
At 12 months, this difference increased to 1.01 SD.
In the univariate mixed-effects linear regression 
analysis, the variables clinical group, age and exposure 
to antiretroviral therapy for PMTCT were signifi cantly 
associated with the weight-for-length z-score. The fi nal 
model (Table) shows a decrease in the weight-for-
length z-score among the infected infants over time 
(p=0.04). At six months, the average difference in the 
weight-for-length z-score between the infected and 
non-infected infants was 0.63 SD. At 12 months, the 
average difference in the weight-for-length z-scores of 
the infected and non-infected infants was 0.87 SD. The 
infants who were exposed to prophylactic treatment to 
prevent the vertical transmission of HIV were 0.75 SD 
heavier than those who were not.
Figure 3 shows the z-scores for the weight-for-length 
measurements by exposure to the prophylactic treat-
ment intended to prevent the vertical transmission 
of HIV. The exposed children were heavier than the 
non-exposed children.
DISCUSSION
In the present study, no signifi cant difference was 
observed between the HIV-infected and non-infected 
infants in terms of their weight and length at birth. 
Similar results have been reported in other studies.9,17 
The growth of the HIV-infected infants is affected by 
the disease, as shown in the differences between the 
weight-for-age, length-for-age and weight-for-length 
z-scores of this group when compared to those of the 
non-infected infants at six and 12 months.
The effect of intra-utero exposure to antiretrovirals 
on the growth pattern of HIV-uninfected infants is 
controversial. Many previous studies did not report 
differences between exposed and non-exposed 
infants.7,8,11,15,17 However, one previous study reported 
a lower birth weight in exposed infants,4 which was 
likely due to differences in the antiretroviral regimens. Ta
bl
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In the present study, the infants exposed to prophylactic 
treatment were heavier for their length than the children 
who were not exposed; this effect remained over time. 
The prophylactic treatment may refl ect the patterns of 
health care and diet between the treated and non-treated 
mothers/infants.
A decrease over time was observed in the weight-for-
age, length-for-age and weight-for-length z-scores of the 
infected infants. Similar results have been reported in a 
study conducted by Berhane et al3 (1997) in a Uganda 
cohort. Growth impairment may be a consequence of 
the general debilitation caused by frequent opportu-
nistic infections and the effects of these infections on 
the ingestion of food, nutrient absorption and energy 
expenditure. In addition, the literature suggests that viral 
replication is associated with growth impairment.2,10
The non-infected infants were evaluated at their fi rst 
medical appointment after birth at a younger age than 
the infected infants. This fi nding may be explained by 
the fact that 95.8% of the mothers of the non-infected 
infants were followed up by the medical service of the 
HIV-specialized center, whereas only 66.7% of the 
mothers of the infected infants received this follow-
up. The monitoring process that occurred throughout 
pregnancy may have caused these infants to be seen 
earlier by the team of pediatricians.
Because there were two types of individuals within 
the HIV-infected group (i.e., antiretroviral-therapy-
treated and non-treated), various stages of the disease 
and differential treatments were present. Therefore, 
the diminished nutritional status observed amongst 
the HIV-infected infants may be a consequence of the 
progress of the disease in the treated and non-treated 
infants. In addition, the status may be associated with 
factors that were not evaluated in the present study (e.g., 
diminished ingestion of food, co-infections, side-effects 
of medication, resistance to antiretroviral therapy and 
adherence to treatment).
Because the infants of the Belo Horizonte cohort were 
regularly followed up in a specialized HIV referral 
center and many were born to mothers who underwent 
prenatal examination at the same institution, it is unli-
kely that these results were a consequence of selection 
bias. The choice of the comparison group (HIV-exposed 
but uninfected infants) appropriately controlled for 
many of the differences in the socioeconomic status and 
social backgrounds that may exist between the children 
of HIV-positive and HIV-negative mothers; however, 
this choice of controls is unable to separate the effects of 
HIV infection from social factors. Because information 
about food ingestion, socioeconomic data and clinical 
information were absent in the medical records, it was 
not possible to establish whether the diminished growth 
observed among HIV-infected children was caused by a 
reduced ingestion of food and nutrients, the side effects 
of medication, co-infections or the evolution of the 
disease. As is common in open cohort studies, the hete-
rogeneity at the follow-up time points may represent 
a limitation of the present study. Several of the infants 
who were younger than 18 months when the analysis 
was performed were censored. Therefore, the reduced 
number of measurements at the end of the follow-up 
period for these infants may have compromised the 
growth model estimates.
The early and severe impacts of an HIV infection on 
growth parameters emphasizes the need for the iden-
tifi cation of HIV-infected infants in the fi rst weeks of 
life, followed by the implementation of nutritional 
interventions during care and treatment. Because of the 
close association of growth with immune function and 
the clinical progression for HIV-infected children, an 
understanding of the growth patterns of HIV-infected 
infants may represent an important tool for targeting 
infants for further assessment. Timely growth monito-
ring may be used to identify infants with suboptimal 
growth, to ensure the provision of appropriate care and 
treatment to these children and to help improve their 
clinical course and quality of life.
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